Latest Asia Pacific News

Ava Risk Group expects FY2026 revenue around $29 million, below prior guidance, due to delayed orders mainly in the Middle East and North America. Despite this, sales intake exceeded revenue, underpinning a strong backlog and positive EBITDA.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.

OpenLearning has locked in a four-year SaaS contract with Holy Cross of Davao College, marking its biggest deal through the CE-Logic reseller channel and reinforcing its foothold in the Philippine education sector.

Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

HALO Technologies launches a convertible notes offer aiming to raise up to A$6.75 million, backing platform upgrades and expansion across Asia-Pacific and adviser networks.

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

DXN Limited has landed a $1 million contract to deliver a Cable Landing Station in American Samoa, reinforcing its foothold in Pacific telecom infrastructure while divesting a non-core Tasmanian data centre.